ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

ClinicalTrials.gov ID: NCT05178862

Public ClinicalTrials.gov record NCT05178862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)

Study identification

NCT ID
NCT05178862
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Scynexis, Inc.
Industry
Enrollment
68 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2, 2022
Primary completion
Nov 6, 2025
Completion
Dec 15, 2025
Last update posted
Dec 18, 2025

2022 – 2025

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
University of Alabama at Birmingham School of Medicine Birmingham Alabama 70121
Banner University Medical Center-Tucson Tucson Arizona 85719
UC Davis Medical Center Sacramento California 95817
UCSF School of Medicine San Francisco California 94143
University of Colorado Anschutz Medical Campus Denver Colorado 80291
Augusta University Medical Center Augusta Georgia 30912
University of Chicago Medical Center Chicago Illinois 60637
Ochsner Medical Center New Orleans Louisiana 70121
LSU Health Sciences Center Shreveport Louisiana 71103
University of Maryland Medical Center Baltimore Maryland 21201
Johns Hopkins Hospital Baltimore Maryland 21287
University of Michigan Hospital Ann Arbor Michigan 48109
Henry Ford Hospital Detroit Michigan 48202
University of Minnesota Medical Center Minneapolis Minnesota 55455
Mayo Clinic - Rochester Rochester Minnesota 55905
Washington University School of Medicine St Louis Missouri 63110
Mercury Street Medical Group, PLLC Butte Montana 59701
Duke University Durham North Carolina 27710
University of Pennsylvania School of Medicine Philadelphia Pennsylvania 19104
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15260

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05178862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05178862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →